Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia
Chi Young Ok(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(Chinese Academy of Agricultural Sciences), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Peng Wei, Jeffrey L. Jorgensen(The University of Texas MD Anderson Cancer Center), Mark J. Routbort(The University of Texas MD Anderson Cancer Center), Dawen Sui, Guilin Tang(The University of Texas MD Anderson Cancer Center), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Rajyalakshmi Luthra, Zhenya Tang(University of Nebraska Medical Center), Sa A. Wang(Beijing Institute of Technology), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), L. Jeffrey Medeiros(Delaware Division of Libraries), Zhuang Zuo(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)
Cited by 82
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k